Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children

Nishio, Naomichi; Yagasaki, Hiroshi; Takahashi, Yoshiyuki; Muramatsu, Hideki; Hama, Asahito; Tanaka, Makito; Yoshida, Nao; Watanabe, Nobuhiro; Kudo, Kazuko; Yoshimi, Ayami; Kojima, Seiji

doi:10.1038/bmt.2009.33

Cited by 50 publications

(44 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These forms of pulmonary disease are strongly associated with cGvHD and therefore, although not pathophysiologically fully understood, are being considered potential forms of pulmonary cGVHD (Cooke and Hildebrandt 2006;Tichelli et al 2008;Bolanos-Meade and Chien 2009;Patriarca et al 2004;Sakaida et al 2003;Savani et al 2006;Nishio et al 2009;Freudenberger et al 2003;Uderzo et al 2007). A murine model of BO following allogeneic HSCT has been lacking until recently when Panoskaltsis-Mortari et al demonstrated the development of obliterative changes in lungs of allogeneic recipients along with increasing levels of CXCL1 (human CXCL8) (Panoskaltsis-Mortari et al 2007).…”

Section: The Role Of the Chemokine-chemokine Receptor System In Cgvhdmentioning

confidence: 96%

The Chemokine System: A Possible Therapeutic Target in Acute Graft Versus Host Disease

Kittan

2010

The Chemokine System in Experimental and Clinical Hematology

View full text Add to dashboard Cite

Allogeneic hematopoetic stem cell transplantation often presents the only chance for cure in a number of malignant and nonmalignant hematologic diseases. However, its beneficial effects are counterweighed by the development of potentially lethal complications, most importantly the development of acute and chronic graft-vs.-host disease (GVHD). Alloantigen-reactive immune responses mediate injury and destruction of GVHD target organs, including the gastrointestinal tract, the liver, the skin, and the lung. Donor leukocyte infiltration into the respective tissues is orchestrated by interactions between chemokines and chemokine receptors, which will be reviewed using a basic science - clinical comparative approach.

show abstract

Section: The Role Of the Chemokine-chemokine Receptor System In Cgvhdmentioning

confidence: 96%

The Chemokine System: A Possible Therapeutic Target in Acute Graft Versus Host Disease

Kittan

2010

The Chemokine System in Experimental and Clinical Hematology

View full text Add to dashboard Cite

show abstract

“…Thus, in lung transplanted patients HLA mismatch confers an increased risk, 18 and signs of BO after HSCT is often accompanied by alloreactivity in other organs (for example, skin, liver and eyes). 1,[3][4][5][6][7][8][19][20][21][22] The essential role of T-cellmediated allorecognition was further indicated by a study showing reduced frequency of BO in HSCT patients receiving a T-cell-depleted graft. 23 Other reported risk factors are BU-based conditioning regimens, 9,24-26 the intensity of conditioning, 27 time from leukaemia diagnosis to HSCT, peripheral blood-derived stem cell source, grade II-IV acute GvHD (aGvHD), 9 pre-transplant airflow obstruction and viral respiratory tract infection within the first 100 days after HSCT.…”

Section: Pathogenesismentioning

confidence: 99%

“…1 Respiratory symptoms include cough, dyspnoea and wheeze, but patients may remain relatively asymptomatic despite moderate-to-severe obstruction. The pronounced variability in reported incidences (1.7-26%) and mortality rates (21-100%) [2][3][4][5][6][7][8][9][10][11] of BO may be because of the lack of consistent definitions. [11][12][13][14][15][16] No validated treatment protocol has been established.…”

Section: Introductionmentioning

confidence: 99%

Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options

Uhlving

Buchvald

Heilmann

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Bronchiolitis obliterans (BO) following allogeneic haematopoietic SCT (HSCT) is a serious complication affecting 1.7-26% of the patients, with a reported mortality rate of 21-100%. It is considered a manifestation of chronic graftversus-host disease, but our knowledge of aetiology and pathogenesis is still limited. Diagnostic criteria are being developed, and will allow more uniform and comparable research activities between centres. At present, no randomised controlled trials have been completed that could demonstrate an effective treatment. Steroids in combination with other immunosuppressive drugs still constitute the backbone of the treatment strategy, and results from our and other centres suggest that monthly infusions of high-dose pulse i.v. methylprednisolone (HDPM) might stabilise the disease and hinder progression. This article provides an overview of the current evidence regarding treatment options for BO and presents the treatment results with HDPM in a paediatric national HSCT-cohort.

show abstract

“…[2][3][4][5][6][7][8]10 However, few reports have analyzed the risk factors for IPS in pediatric HSCT recipients. [14][15][16][17] In this regard, the present study provides valuable information on pediatric HSCT. The cumulative incidence of IPS at 120 days after conventional HSCT in the present study (6.7%) was similar to previously reported incidence rates using a similar definition of the syndrome and comparable diagnostic procedures.…”

Section: Discussionmentioning

confidence: 99%

Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children

Sano

Kobayashi

Iguchi

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

Idiopathic pneumonia syndrome (IPS) is a critical complication following allogeneic hematopoietic SCT (HSCT); however, few reports have analyzed the risk factors for IPS in children. A total of 210 consecutive pediatric patients, including 131 boys and 79 girls, with various hematologic malignancies, aplastic anemia or solid tumors who underwent allogeneic HSCT were analyzed to clarify the incidence and risk factors for IPS. Patient and transplantation characteristics after allogeneic HSCT were compared between patients with and without IPS. Cumulative incidence rates of IPS 120 days after allogeneic HSCT were 6.7% (14/210). Of 14 patients with IPS, 11 (78.6%) died after developing IPS. The presence of prior HSCT was more frequent in patients with IPS (IPS group) than in those without IPS (non-IPS group; 35.7 vs 12.8%, respectively, P ¼ 0.018). The IPS group contained more patients with acute GVHD (grade II-IV) than the non-IPS group (50.0 vs 18.9%, respectively, P ¼ 0.006). The association of these two factors with IPS was further confirmed by multivariate analysis. We should be aware of these risk factors in patients who have undergone allogeneic HSCT.

show abstract

Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children

Cited by 50 publications

References 31 publications

The Chemokine System: A Possible Therapeutic Target in Acute Graft Versus Host Disease

The Chemokine System: A Possible Therapeutic Target in Acute Graft Versus Host Disease

Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options

Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children

Contact Info

Product

Resources

About